What To Know
- Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.
- Together, they will bring One Drop’s multi-analyte dermal biosensor to market, making continuous health sensing more accessible and available at a lower cost to people living with type 1 diabetes, type 2 diabetes, and other chronic conditions.
One Drop, a leader in precision health solutions for people living with chronic conditions, today announced Carrie Siragusa, CPA, as VP of Commercial Strategy.
Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.
Siragusa brings more than 15 years of financial, operational, and marketing experience in public and private organizations in the pharmaceutical, health sciences, and life sciences industries to One Drop. Before joining One Drop, Siragusa led the Innovation and Diabetes Portfolio team at Sanofi, a leading global biopharmaceutical company focused on human health. While at Sanofi, Siragusa was responsible for leading marketing for key diabetes brands and managing patient support programs. She also served as the US lead for the organization’s integrated care offerings. Prior to Sanofi, Siragusa served as an auditor at EisnerAmper LLP, a leading full-service accounting and advisory firm. Siragusa is a Certified Public Accountant (CPA).
“We are thrilled to have Carrie join our team to help accelerate the use of our predictive technology to empower people living with chronic conditions,” said Jeff Dachis, One Drop CEO and founder. “Carrie’s expertise in innovation within the diabetes space will be an incredible asset to One Drop as we explore ways to make continuous glucose monitoring more accessible and affordable to all.”
Siragusa will report to Rachel Yap Martens, SVP of Commercial Strategy and Innovation. Together, they will bring One Drop’s multi-analyte dermal biosensor to market, making continuous health sensing more accessible and available at a lower cost to people living with type 1 diabetes, type 2 diabetes, and other chronic conditions. In her new role, Siragusa will work closely with Ashwin Pushpala and Matthew Chapman, SVPs of Biosensor Development. The biosensor will generate a continuous stream of thousands of additional data points per member per day, offering exponential growth of the 26 billion existing health data points powering One Drop’s predictive, AI-enabled platform.
“Our team is laser-focused on making continuous health sensing technology available to a broader at-risk audience,” said Yap Martens. “When coupled with One Drop’s telehealth platform and predictive capabilities, our biosensors will have the power to deliver personalized, preventative care to millions of more people worldwide, empowering them to take charge of their health today for a better, healthier tomorrow.”
